Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review

Chruścik, Anna; Lam, Alfred King‐Yin

doi:10.1016/j.yexmp.2015.08.013

Cited by 41 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs serve important roles in the formation and progression of PTC by regulating numerous physiological and pathological behaviours (24,25). Hence, investigating the functional roles of specific miRNAs in PTC may contribute in identifying effective therapeutic targets for the management of patients with PTC.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

Liu

Guo²,

Chai

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

MicroRNAs (miRs) serve important roles in the formation and progression of papillary thyroid cancer (PTC) by regulating numerous physiological and pathological behaviours. Thus, investigating the functional roles of specific miRNAs in PTC may contribute in identifying effective therapeutic targets for the management of patients with PTC. miR-744 is emerging as a cancer-associated miRNA in numerous types of human cancers; however, the expression and specific functions of miR-744 in PTC are yet to be determined, and the mechanism underlying the regulatory roles of miR-744 in PTC remains unknown. In the present study, miR-744 expression was significantly decreased in PTC tissues and cell lines, as detected by reverse transcription-quantitative polymerase chain reaction. miR-744 restoration inhibited cell proliferation and invasion in PTC. Bioinformatics analysis predicted NIN1 (RPN12) binding protein 1 homolog (NOB1) as a potential target of miR-744. Subsequent experiments validated NOB1 as a direct target gene of miR-744 in PTC. Furthermore, NOB1 was upregulated in PTC tissues and negatively correlated with miR-744 expression. NOB1 overexpression could counteract miR-744-mediated antitumor effects on PTC cells. In summary, these findings indicated that miR-744 may inhibit the progression of PTC by directly targeting NOB1. The identification of the miR-744/NOB1 axis may provide insight into potential targets for the treatment of patients with PTC and improve their prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

Liu

Guo²,

Chai

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Molecular prognostication of DTC may be further improved by the use of microRNAs (miRNAs), which are short (about 19-22 nucleotides), non-coding RNA sequences having relevant role in cancer development and progression through their regulatory activity on gene expression at both the transcriptional and post-transcriptional levels (Calin et al 2002, Ma et al 2007. To date, dysregulation of several miRNAs has been demonstrated in PTC, and the actual prognostic implication of these genetic features represents a hot point of current research (Chruscik & Lam 2015). Possible prognostic role of miRNA patterns in PTC was suggested in a breakthrough study by Gao and coworkers (2010).…”

Section: :11mentioning

confidence: 99%

Application of molecular biology of differentiated thyroid cancer for clinical prognostication

Marotta¹,

Sciammarella²,

Colao³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Although cancer outcome results from the interplay between genetics and environment, researchers are making a great effort for applying molecular biology in the prognostication of differentiated thyroid cancer (DTC). Nevertheless, role of molecular characterisation in the prognostic setting of DTC is still nebulous. Among the most common and well-characterised genetic alterations related to DTC, including mutations of BRAF and RAS and RET rearrangements, BRAF V600E is the only mutation showing unequivocal association with clinical outcome. Unfortunately, its accuracy is strongly limited by low specificity. Recently, the introduction of next-generation sequencing techniques led to the identification of TERT promoter and TP53 mutations in DTC. These genetic abnormalities may identify a small subgroup of tumours with highly aggressive behaviour, thus improving specificity of molecular prognostication. Although knowledge of prognostic significance of TP53 mutations is still anecdotal, mutations of the TERT promoter have showed clear association with clinical outcome. Nevertheless, this genetic marker needs to be analysed according to a multigenetic model, as its prognostic effect becomes negligible when present in isolation. Given that any genetic alteration has demonstrated, taken alone, enough specificity, the co-occurrence of driving mutations is emerging as an independent genetic signature of aggressiveness, with possible future application in clinical practice. DTC prognostication may be empowered in the near future by non-tissue molecular prognosticators, including circulating BRAF V600E and miRNAs. Although promising, use of these markers needs to be refined by the technical sight, and the actual prognostic value is still yet to be validated. 23:11Review V Marotta et al. Molecular prognosis in thyroid cancer

show abstract

“…Since their initial discovery, it has been demonstrated that this class of non‐coding RNA is involved in regulating many biological pathways in a variety of multicellular organisms, including humans (Jansson and Lund, ). In relation to cancer, miRNAs can act as oncogenes or tumour suppressor genes, depending on their regulatory targets (Ebrahimi et al., ; Gopalan et al., , ; Maroof et al., , ; Amin and Lam, ; Chruścik and Lam, ). Also, miRNAs have been implicated as robust regulators in both normal and cancer stem cells (CSCs).…”

Section: Introductionmentioning

confidence: 99%

“…In relation to progenitors; MIF, Macrophage migration inhibitory factor; miRNA, MicroRNAs; miRNPs, micro-RNPs; MMP16, Matrix metalloproteinase 16; MSI1, musashi RNA-binding protein 1; MTSS1, Metastasis suppressor 1; MYB, v-myb avian myeloblastosis viral oncogene homolog; NF-ĸB, Nuclear factor kappa-lightchain-enhancer of activated B cells; PTEN, phosphatase and tensin homolog; qRT-PCR, Quantitative real time PCR; Rb, Retinoblastoma; RHOB, Ras homolog family member B; Sox2, SRY-sex determining region Y-box2; SP, Side population; Src-v, Src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; TCF/LEF, T Cell-Specific Transcription Factor/ lymphoid enhancer-binding factor; TCF4, Transcription factor 4; TGFβ, Transforming Growth Factor Beta; TLE4, Transducin-like Enhancer of Split type 4; TS, Thymidylate Synthetise; VEGF-C, Vascular endothelial growth factor C; Wnt, Wingless/Int. cancer, miRNAs can act as oncogenes or tumour suppressor genes, depending on their regulatory targets Gopalan et al, 2014Gopalan et al, , 2015Maroof et al, 2014aMaroof et al, , 2014bAmin and Lam, 2015;Chruścik and Lam, 2015). Also, miRNAs have been implicated as robust regulators in both normal and cancer stem cells (CSCs).…”

Section: Introductionmentioning

confidence: 99%

Modulatory roles of microRNAs in the regulation of different signalling pathways in large bowel cancer stem cells

Mamoori

Gopalan

Smith

et al. 2016

Biology of the Cell

Self Cite

View full text Add to dashboard Cite

There are emerging data to suggest that microRNAs (miRNAs) have significant roles in regulating the function of normal cells and cancer stem cells (CSCs). This review aims to analyse the roles of miRNAs in the regulation of colon CSCs through their interaction with various signalling pathways. Studies showed a large number of miRNAs that are reported to be deregulated in colon CSCs. However, few of the studies available were able to outline the function of miRNAs in colon CSCs and uncover their signalling pathways. From those miRNAs, which are better described, miR-21 followed by miR-34, miR-200 and miR-215 are the most reported miRNAs to have roles in colon CSC regulation. In particular, miRNAs have been reported to regulate the stemness features of colon CSCs mainly via Wnt/B-catenin and Notch signalling pathways. Additionally, miRNAs have been reported to act on processes involving CSCs through cell cycle regulation genes and epithelial-mesenchymal transition. The relative paucity of data available on the significance of miRNAs in CSCs means that new studies will be of great importance to determine their roles and to identify the signalling pathways through which they operate. Such studies may in future guide further research to target these genes for more effective cancer treatment. miRNAs were shown to regulate the function of cancer stem cells in large bowel cancer by targeting a few key signalling pathways in cells.

show abstract

Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review

Cited by 41 publications

References 30 publications

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

Application of molecular biology of differentiated thyroid cancer for clinical prognostication

Modulatory roles of microRNAs in the regulation of different signalling pathways in large bowel cancer stem cells

Contact Info

Product

Resources

About